Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia

Journal of Applied Genetics

Volumn 53, Issue 1, 2012, Pages 83-91

  Szczepanek, Joanna ^a,b   Jarzab, Michal ^c   Oczko Wojciechowska, Malgorzata ^c   Kowalska, Malgorzata ^c   Tretyn, Andrzej ^b   Haus, Olga ^a   Pogorzala, Monika ^a   Wysocki, Mariusz ^a   Jarzab, Barbara ^c   Styczynski, Jan ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Acute leukemia; Children; Drug resistance; Gene expression profiles; Microarrays

Indexed keywords

ANTINEOPLASTIC AGENT; RNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIOPSY; BONE MARROW CELL; CHEMISTRY; CHILD; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW CELLS; CHILD; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, NEOPLASM; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84856287547     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13353-011-0073-x     Document Type: Article

References (47)

1. Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215-2222.
2. Bachman KE, Argani P, Samuels Y et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
3. Bhojwani D, Kang H, Menezes RX et al (2008) Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 26: 4376-4384.
4. Blohm DH, Guiseppi-Elie A (2001) New developments in microarray technology. Curr Opin Biotechnol 12: 41-47.
5. Brown JR, Auger KR (2011) Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol 11: 4.
6. Cheok MH, Yang W, Pui CH et al (2003) Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34: 85-90.
7. den Boer ML, Pieters R, Kazemier KM et al (1998) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91: 2092-2098.
8. den Boer ML, Harms DO, Pieters R et al (2003) Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21: 3262-3268.
9. Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429: 464-468.
10. Ferrando AA, Neuberg DS, Staunton J et al (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87.
11. Garza-González E, Bosques-Padilla FJ, Pérez-Pérez GI et al (2004) Association of gastric cancer, HLA-DQA1, and infection with Helicobacter pylori CagA+ and VacA+ in a Mexican population. J Gastroenterol 39: 1138-1142.
12. Györffy B, Surowiak P, Kiesslich O et al (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712.
13. Hoelzer D, Gökbuget N, Ottmann O et al (2002) Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 162-192.
14. Hofmann WK, de Vos S, Elashoff D et al (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359: 481-486.
15. Holleman A, Cheok MH, den Boer ML et al (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351: 533-542.
16. Holleman A, den Boer ML, de Menezes RX et al (2006) The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 107: 769-776.
17. Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562-4567.
18. Jarzab B, Gubała E, Lange D (2005) DNA microarrays and papillary thyroid carcinoma gene expression profile. Endokrynol Pol 56: 293-301.
19. Jeha S, Pui CH (2009) Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23: 973-990.
20. Lugthart S, Cheok MH, den Boer ML et al (2005) Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7: 375-386.
21. McLennan AG (2006) The Nudix hydrolase superfamily. Cell Mol Life Sci 63: 123-143.
22. Mildvan AS, Xia Z, Azurmendi HF et al (2005) Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys 433: 129-143.
23. Möricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111: 4477-4489.
24. Möricke A, Zimmermann M, Reiter A et al (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24: 265-284.
25. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
26. Planelles D, Nagore E, Moret A et al (2006) HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol 154: 261-266.
27. Pui CH (2009) Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 27: 5121-5123.
28. Pui CH, Campana D, Pei D et al (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360: 2730-2741.
29. Riemersma SA, Jordanova ES, Schop RF et al (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96: 3569-3577.
30. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82.
31. Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
32. Schotte D, Pieters R, Den Boer ML (2011a) MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia (in press). doi: 10. 1038/leu. 2011. 151.
33. Schotte D, De Menezes RX, Moqadam FA et al (2011b) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96: 703-711.
34. Shah AA, Meese E, Blin N (2010) Profiling of regulatory microRNA transcriptomes in various biological processes: a review. J Appl Genet 51: 501-507.
35. Staal FJ, de Ridder D, Szczepanski T et al (2010) Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia 24: 491-499.
36. Styczyński J, Wysocki M (2004) Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22: 963-964.
37. Styczynski J, Pieters R, Huismans DR et al (2000) In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 110: 813-818.
38. Styczynski J, Wysocki M, Debski R et al (2002) Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia. Leuk Lymphoma 43: 1843-1848.
39. Styczynski J, Wysocki M, Dluzniewska A et al (2008) Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Res 28: 1927-1931.
40. Szczepanek J, Styczyński J, Haus O et al (2007) Gene expression profiles in acute lymphoblastic leukemia in children and adults. Postepy Hig Med Dosw (Online) 61: 519-533.
41. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165.
42. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38: 94-110.
43. Vigorito E, Billadeu DD, Savoy D et al (2003) RhoG regulates gene expression and the actin cytoskeleton in lymphocytes. Oncogene 22: 330-342.
44. Vilar E, Mukherjee B, Kuick R et al (2009) Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15: 2829-2839.
45. Willenbrock H, Juncker AS, Schmiegelow K et al (2004) Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 18: 1270-1277.
46. Yeoh EJ, Ross ME, Shurtleff SA et al (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143.
47. Zaza G, Cheok M, Yang W et al (2005) Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106: 1778-1785.